References
1. Andersen C.J., Murphy K.E., Fernandez M.L. Impact of obesity and metabolic syndrome on immunity. Adv. Nutr. 2016; 7 (1): 66–75. DOI: https://doi.org/10.3945/an.115.010207
2. Feuerer M., Herreto L., Cipolletta D., Naaz A., Wong J., Nayer A., Lee J., Goldfine A.B., Benoist C., Shoelson S. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009; 15: 930–9. DOI: https://doi.org/10.1038/nm.2002
3. Rius B., Lopez-Vicario C., Gonzalez-Periz A., Moran-Salvador E., Garcia-Alonso V., Claria J., Titos E. Resolusion of inflammation in obesity-induced liver disease. Front. Immunol. 2012; 3: 257. DOI: https://doi.org/10.3389/fimmu.2012.00257
4. Karlsson E.A., Sheridan P.A, Beck M.A. Diet-induced obesity in mice reduces the maintenance of influenza-specific CD8+ memory T cells J. Nutr. 2010; 140: 1691–7. DOI: https://doi.org/10.3945/jn.110.123653
5. Kanneganti T.D., Dixit V.D. Immunological complication of obesity. Nat. Immunol. 2012; 13: 707–12. DOI: https://doi.org/10.1038/ni.2343
6. Yang H., Youm Y.H., Vandanmagsar B., Ravussin A., Gimble J.M., Greenway F., Stephens J.M., Mynatt R.L, Dixit V.D. Obesity increases the production of proinflammatory mediators from adipose tissue T cell and compromises TCR receptoire diversity implications for systemic inflammation and insulin resistance. J. Immunol. 2010; 185: 1836–45. DOI: https://doi.org/10.4049/jimmunol.1000021
7. Guilherme A., Virbasius J.V.. Puri V., Czech M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008; 9: 231–7. DOI: https://doi.org/10.1038/nrm2391
8. Belizário J.E., Faintuch J., Garay-Malpartida M. Gut microbiome dysbiosis and immunometabolism: new frontiers for treatment of metabolic diseases. Mediators Inflamm. 2018; 2018: 2037838. DOI: https://doi.org/10.1155/2018/2037838
9. Plotnikova E.Yu., Krasnov O.A. Metabolic syndrome and intestinal microbiota: what is common? Experimental and clinical gastroenterology. 2014; 112 (12): 64–73. (in Russian)
10. Zverev V.V., Maksimova O.V., Gervazieva V.B. Intestinal microbiota and its relationship with obesity. Infectious diseases. 2014; 12 (3): 69–79. (in Russian)
11. O’Rourke R.W., Kay T., Scholz M.H., Diggs B., Jobe B.A., Lewinsohn D.M., Bakke A.C. Alteration in T-cell subset frequency in peripheral blood in obesity. Obes. Surg. 2005; 15: 1463–8. DOI: https://doi.org/10.1381/096089205774859308
12. Salikhova A.F., Farkhutdinova L.M. The role of cytokines in the pathogenesis of obesity. Cytokines and inflammation. 2013; 12 (3): 21–4. (in Russian)
13. Van der Weerd K., Dik W.A., Schrijver B., Schweitzer D.H., Langerak A.W., Drexhage H.A., Kiewiet R.M., et al. Morbidly obese human subjects have increased peripheral blood CD4+ T cells with skewing toward a Treg and Th2-dominated phenotype. Diabetes. 2012; 61: 401–8. DOI: https://doi.org/10.2337/db11-1065
14. Issazadeh-Navikas S., Teimer R., Bockermann R. Influence of dietary components on regulatory T cells. Mol. Med. 2012; 18: 95–110. DOI: https://doi.org/10.2119/molmed.2011.00311
15. Huand P.L. A comprehensive definition for metabolic syndrome. Dis. Model. Mech. 2009; 2: 231–7. DOI: https://doi.org/10.1242/dmm.001180
16. Maciver N.J., Jacobs S.R., Wieman H.L., Wofford J.A., Coloff J.L., Rathmell J.C. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J. Leukoc. Biol. 2008; 84: 949–57. DOI: https://doi.org/10.1189/jlb.0108024
17. Viardot A., Grey S.T., Mackay F., Chisholm D. Potential anti-inflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology. 2007; 148: 346–53. DOI: https://doi.org/10.1210/en.2006-0686
18. Jagannathan-Bogdan M., McDonnell M.E., Shin H., Rehman Q., et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J. Immunol. 2011; 186: 1162–72. DOI: https://doi.org/10.4049/jimmunol.1002615
19. Teoh H., Quan A., Bang G., Wang G., Lovren F., Vu V., Haitsma J.J., Szmitko P.E., Al-Omran M., Wang C.H. Adiponectin deficiency promotes endothelial activation and promofoundly exacerbates sepsis-related mortality. Am. J. Physiol. Endocrinol. Metab. 2008; 295: E658–64. DOI: https://doi.org/10.1152/ajpendo.90384.2008
20. Makarova M.N., Makarov V.G., Diet-induced models of metabolic disorders, experimental metabolic syndrome. Laboratory animals for scientific research. 2018; 1: 79–91. (in Russian)
21. Johnston T.P. The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J. Cardiovasc. Pharmacol. 2004; 43 (4): 595–606. DOI: https://doi.org/10.1097/00005344-200404000-00016
22. Lacraz G., Rakotoarivelo V., Labbé S.M., Vernier M., Noll C., Mayhue M., Stankova J., Schwertani A., Grenier G., Carpentier A., Richard D., Ferbeyre G., Fradette J., Rola-Pleszczynski M., Menendez A., Langlois M.F., Ilangumaran S., Ramanathan S. Deficiency of Interleukin-15 confers resistance to obesity by diminishing inflammation and enhancing the thermogenic function of adipose tissues. PLoS One. 2016; 11 (9): e0162995. DOI: https://doi.org/10.1371/journal.pone.0162995
23. Barra N.G., et al. Interleukin-15 contributes to the regulation of murine adipose tissue and human adipocytes. Obesity (Silver Spring). 2010; 18 (8): 1601–7. DOI: https://doi.org/10.1038/oby.2009.445
24. Yilmaz H. Decreased circulating levels of IL-22 in newly diagnosed metabolic syndrome patients. J. Clin. Anal. Med. 2018; 9 (4): 310–4.
25. Dudakov J.A. Interleukin-22: immunobiology and pathology. Annu. Rev. Immunol. 2015; 33: 747–85. DOI: https://doi.org/10.1146/annurev-immunol-032414-112123
26. Park O., et al. Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences. Cell Biosci. 2015; 5: 25. DOI: https://doi.org/10.1186/s13578-015-0015-0
27. Zenewicz L.A. IL-22: there is a gap in our knowledge. Immuno Horizons. 2018; 2 (6): 198–207. DOI: https://doi.org/10.4049/immunohorizons.1800006
28. Salikhova A.F., Farkhutdinova L.M. Immunological shifting in obesity and their relationship with disorders of carbohydrate metabolism. Medical immunology. 2013; 15 (5): 465–70. (in Russian)
29. Ballak D.B., Stienstra R., et al. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015; 75 (2): 280–90. DOI: https://doi.org/1016/j.cyto.2015.05.005
30. Silvia de Barros-Mazon S., Marin D.M., de Carvalho C.P., Alegre S.M. Inflammatory and metabolic markers in pre- and post- treatment of obesity. Antiobes. Drug Discov. Dev. 2011; 1: 49–66. DOI: https://doi.org/10.2174/978160805163211101010049
31. Perminova O.M., Volsky N.N., Kudaeva O.T., Goyman E.V., Kozlov V.A. Dyslipidemia and Th1/Th2 ratio at different stages of chronic «graft versus host» reaction development. Immunologiya. 2009; 30 (6): 341–5. (in Russian)